No Data
GRI Bio Raises $13.9M In Gross Proceeds Since Start Of 2024; Funds Expected To Extend Cash Runway Into Mid-Q1 2025, Supporting Interim Data From Phase 2a Study Of GRI-0621 For Idiopathic Pulmonary Fibrosis (IPF) Treatment
Top Midday Decliners
Dow Falls Over 150 Points; General Motors Tops Q3 Views
Wall Street Set to Open Lower as Investors Await Earnings Report, Harker Speech
GRI Bio GRI Warrants Exercised; Immunic IMUX Phase 3 IDMC Recommendation
Investors Await Earnings Reports as US Futures Move Lower Tuesday Pre-Bell
No Data
No Data